Online inquiry

IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4620MR)

This product GTTS-WQ4620MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4620MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14874MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ885MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ13275MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-06252616
GTTS-WQ5198MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ11986MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MM-005
GTTS-WQ4787MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BT 5/9
GTTS-WQ4770MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ12583MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NV-02
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW